Cempra looking for $100M on back of solithromycin data

Cempra Inc. (NASDAQ:CEMP) said its oral solithromycin ( CEM-101) met the primary endpoint in the Phase III Solitaire-Oral trial to treat community acquired bacterial pneumonia (CABP) and proposed to raise up to $100 million in a follow-on.

Among 860 patients with moderate to severe CABP, CEM-101 showed non-inferiority to moxifloxacin as measured by early clinical response after 72 hours. Response rates were 78.2% for the oral solithromycin group and 77.9% for the moxifloxacin group, with a 95% confidence interval from -5.5% to 6.1%. Patients were randomized to receive once-daily oral solithromycin for five days or once-daily moxifloxacin for seven days. ...